Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Fisher & Paykel ups pre-Christmas dividend
Markets

Fisher & Paykel ups pre-Christmas dividend

And employees will get a share of $4 million.

ERoad half-year earnings reflect straighter steering
Markets

ERoad half-year earnings reflect straighter steering

Cash burn under control, strong potential in North America.

Ben Moore 11:10am
Ryman Healthcare cites ‘challenging’ housing market in 4pc net profit drop
Markets

Ryman Healthcare cites ‘challenging’ housing market in 4pc net profit drop

New Zealand’s largest listed retirement company cited the “challenging” housing market in declaring net profit down 4% and downgrading its profit outlook.Ryman Healthcare’s reported net profit after tax fell 4% from $193 million a year ago to $186.7m for the six months to Sept 30...

TradeWindow slashes staff and cash burn
Markets

TradeWindow slashes staff and cash burn

Monthly cash burn of $1m last year should fall to $200,000 by the end of this year.